ASH 2024 | Key CML updates from ASH 2024

There’s a major study that is ASC4FIRST, certainly seeing the long-term follow-up because the approval just came and this provides further evidence and reassurance that it is a valuable addition to the armamentarium for frontline therapy. There was also a study from Australia that was a single-arm study but also using it as frontline and it shows very similar data so again additional evidence that asciminib frontline is a good strategy. There’s been a few studies that are looking at some new drugs that look very attractive – olverembatinib, a drug that’s been approved in China but it’s going through a pivotal trial in the US, looks very attractive, high efficacy, good safety, so we’ll have to wait and see what happens with that pivotal trial but it may be a drug that we’ll end up having available for patients who have received prior therapies. There was another drug that came from China, early Phase I study that also looked at very promising results, again just Phase I but it looks very very attractive. So I think that it is good to see that there continues to be new approaches for frontlines. Certainly, we have very good drugs there, imatinib is good and the others, but we can aim for better outcomes. But it’s also good to see that there are new drugs coming along that may help us for those patients who are most difficult to treat.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.